12th September 2014
Diurnal announces £6m funding round
Diurnal announces £6m funding round
Cardiff-based Diurnal is a pharmaceutical company creating innovative, high-value hormone therapeutics and advanced treatment regimens of approved drugs.
Finance Wales has re-invested alongside IP Group as part of a £6 million investment round. The full £6 million fundraising will enable Diurnal to complete the Phase 3 programme for its lead product Chronocort® as well as to advance certain other pipeline programmes.